528117
PI 3-K抑制剂IX，PIK-90
The PI 3-K inhibitor IX, PIK-90, also referenced under CAS 677338-12-4, controls the biological activity of PI 3-K. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
别名:
PI 3-K抑制剂IX，PIK-90
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H17N5O3
化学文摘社编号:
分子量:
351.36
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
InChI key
ZJAVHOMVDCMAMF-UHFFFAOYSA-N
InChI
1S/C18H17N5O3/c1-25-13-6-5-12-14(15(13)26-2)21-18(23-9-8-20-16(12)23)22-17(24)11-4-3-7-19-10-11/h3-7,10H,8-9H2,1-2H3,(H,21,22,24)
SMILES string
[n]21[c](c3c(nc2NC(=O)c4cnccc4)c(c(cc3)OC)OC)=NCC1
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
pale yellow
solubility
DMSO: 0.5 mg/mL
shipped in
wet ice
storage temp.
−20°C
Quality Level
General description
一种具有细胞渗透性的咪唑喹唑啉化合物，可作为一种针对全部三类PI 3-K激酶（p110α，p110γ、PI 3-KC2α，p110δ，PI 3-KC2β，p110β和hsVPS34的IC50 分别为11，18、47、58、64、350和830 nM）以及几种PIKK（DNA-PK，ATM和mTORC1的IC50 分别为13、610和1050 nM）和PI 4-KIIIα（IC50 =830 nM）的强效、可逆的ATP竞争性抑制剂，同时对PI 4-KIIIβ和ATR的效价大大降低（分别为IC50 =3.1和15 µM），对PI 4-KIIα，PIPK（IC50 >100 µM）以及一组36种常用研究的蛋白激酶（在2.5 µM时为<15% inhibition at 10 µM). Effectively suppreses insulin-stimulated phosphorylations of Akt and rpS6 in 3T3-L1 adipocytes and L6 myotubes in a dose-dependent manner in vitro (by >90%）的活性很小或没有活性，并完全防止小鼠体内胰岛素诱导的血糖下降（10 mg/ml，i.p.）。
Packaging
用惰性气体包装
Preparation Note
复溶后，等分并冷冻保存（-20°C）。贮备液在-20°C下可稳定保存至多3个月。
完全溶解可能需要轻微加热。
Other Notes
Fan, Q.W., et al. 2007.Cancer Res.67, 7960.
Fan, Q.W., et al. 2006.Cancer Cell9, 341.
Knight, Z.A., et al. 2006.Cell125, 733.
Fan, Q.W., et al. 2006.Cancer Cell9, 341.
Knight, Z.A., et al. 2006.Cell125, 733.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lay Teng Ang et al.
Cell, 185(14), 2523-2541 (2022-06-24)
Stem cell research endeavors to generate specific subtypes of classically defined "cell types." Here, we generate >90% pure human artery or vein endothelial cells from pluripotent stem cells within 3-4 days. We specified artery cells by inhibiting vein-specifying signals and vice
Tomoka Takao et al.
STAR protocols, 3(4), 101786-101786 (2022-11-02)
Here, we present a protocol for the selective differentiation of human pluripotent stem cells mimicking human developmental processes into expandable PRRX1+ limb-bud mesenchymal (ExpLBM) cells. This approach enables expansion through serial passage while maintaining capacity for chondrogenic differentiation. For complete
Stephen J Gadomski et al.
iScience, 27(8), 110537-110537 (2024-08-28)
Stem cell therapies for degenerative cartilage disease are limited by an incomplete understanding of hyaline cartilage formation and maintenance. Human bone marrow stromal cells/skeletal stem cells (hBMSCs/SSCs) produce stable hyaline cartilage when attached to hyaluronic acid-coated fibrin microbeads (HyA-FMBs), yet
Alexandra K Eicher et al.
Cell stem cell, 29(1), 36-51 (2021-12-03)
Human organoid model systems lack important cell types that, in the embryo, are incorporated into organ tissues during development. We developed an organoid assembly approach starting with cells from the three primary germ layers-enteric neuroglial, mesenchymal, and epithelial precursors-that were
Keishi Kishimoto et al.
Nature protocols, 17(11), 2699-2719 (2022-08-18)
Development of visceral organs such as the esophagus, lung, liver and stomach are coordinated by reciprocal signaling interactions between the endoderm and adjacent mesoderm cells in the fetal foregut. Although the recent successes in recapitulating developmental signaling in vitro has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持